A Polyaminobiaryl-Based β-secretase Modulator Alleviates Cognitive Impairments, Amyloid Load, Astrogliosis, and Neuroinflammation in APPSwe/PSEN1ΔE9 Mice Model of Amyloid Pathology
Abstract
:1. Introduction
2. Results
2.1. PEL24-199 Restores the Short- and Long-Term Spatial Memory in APP/PS1 Mice
2.2. PEL24-199 Curative Treatment Reduces Plaque Formation and Aβ Deposition in APP/PS1 Mice Brain
2.3. PEL24-199 Reduces the Activation of Astrocytes and Neuroinflammation in APP/PS1 Mice
2.4. PEL24-199 Treatment Increases Phosphatase PP2A and GGA1 Protein Levels in APP/PS1 Mice
3. Discussion
4. Materials and Methods
4.1. Animals
4.2. Drug Treatment
4.3. Behavioral Tests
4.3.1. Actimetry
4.3.2. Elevated Plus Maze
4.3.3. Y-Maze
4.3.4. Barnes Maze
4.4. Sacrifice and Brain Tissue Preparation
4.5. SDS-PAGE and Western Blot
4.6. Immunohistochemistry
4.7. mRNA Extraction and Quantitative Real-Time PCR Analysis
4.8. ELISA
Aβ1-40 and Aβ1-42 Levels in Plasma
4.9. Statistics
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Calderon-Garcidueñas, A.L.; Duyckaerts, C. Alzheimer disease. Handb. Clin. Neurol. 2017, 145, 325–337. [Google Scholar] [CrossRef]
- Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 2002, 297, 353–356. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McGeer, P.L.; McGeer, E.G. Inflammation, autotoxicity, and Alzheimer’s disease. Neurobiol. Aging. 2001, 22, 799–809. [Google Scholar] [CrossRef] [PubMed]
- Rajendran, L.; Annaert, W. Membrane trafficking pathways in Alzheimer’s disease. Traffic 2012, 13, 759–770. [Google Scholar] [CrossRef] [PubMed]
- Hampel, H.; Vassar, R.; De Strooper, B.; Hardy, J.; Willem, M.; Singh, N.; Zhou, J.; Yan, R.; Vanmechelen, E.; De Vos, A.; et al. The β-Secretase BACE1 in Alzheimer’s Disease. Biol. Psychiatry 2021, 89, 745–756. [Google Scholar] [CrossRef]
- Vassar, R.; Bennett, B.D.; Babu-Khan, S.; Kahn, S.; Mendiaz, E.A.; Denis, P.; Teplow, D.B.; Ross, S.; Amarante, P.; Loeloff, R.; et al. Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286, 735–741. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, Z.; Xu, Q.; Cai, F.; Liu, X.; Wu, Y.; Song, W. BACE2, a conditional β-secretase, contributes to Alzheimer’s disease pathogenesis. JCI Insight 2019, 4, e123431. [Google Scholar] [CrossRef] [Green Version]
- De Strooper, B.; Iwatsubo, T.; Wolfe, M.S. Presenilins and γ-secretase: Structure, function, and role in Alzheimer’s Disease. Cold Spring Harb. Perspect. Med. 2012, 2, a006304. [Google Scholar] [CrossRef]
- Postina, R.; Schroeder, A.; Dewachter, I.; Bohl, J.; Schmitt, U.; Kojro, E.; Prinzen, C.; Endres, K.; Hiemke, C.; Blessing, M.; et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. JCI 2004, 113, 1456–1464. [Google Scholar] [CrossRef] [Green Version]
- Palop, J.J.; Mucke, L. Amyloid-β–induced neuronal dysfunction in Alzheimer’s disease: From synapses toward neural networks. Nat. Neurosci. 2010, 13, 812–818. [Google Scholar] [CrossRef] [Green Version]
- Yan, R.; Vassar, R. Targeting the β secretase BACE1 for Alzheimer’s disease therapy. Lancet Neurol. 2014, 13, 319–329. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hu, X.; Das, B.; Hou, H.; He, W.; Yan, R. BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions. J. Exp. Med. 2018, 215, 927–940. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Willem, M.; Dewachter, I.; Smyth, N.; Van Dooren, T.; Borghgraef, P.; Haass, C.; Van Leuven, F. Beta-site amyloid precursor protein cleaving enzyme 1 increases amyloid deposition in brain parenchyma but reduces cerebrovascular amyloid angiopathy in aging BACE x APP[V717I] double-transgenic mice. Am. J. Pathol. 2004, 165, 1621–1631. [Google Scholar] [CrossRef] [PubMed]
- Li, R.; Lindholm, K.; Yang, L.B.; Yue, X.; Citron, M.; Yan, R.; Beach, T.; Sue, L.; Sabbagh, M.; Cai, H.; et al. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer’s disease patients. Proc. Natl. Acad. Sci. USA 2004, 101, 3632–3637. [Google Scholar] [CrossRef] [Green Version]
- Yang, L.B.; Lindholm, K.; Yan, R.; Citron, M.; Xia, W.; Yang, X.L.; Beach, T.; Sue, L.; Wong, P.; Price, D.; et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat. Med. 2003, 9, 3–4. [Google Scholar] [CrossRef]
- Hrabinova, M.; Pejchal, J.; Kucera, T.; Jun, D.; Schmidt, M.; Soukup, O. Is It the Twilight of BACE1 Inhibitors? Curr. Neuropharmacol. 2021, 19, 61–77. [Google Scholar] [CrossRef] [PubMed]
- Kandalepas, P.C.; Vassar, R. The normal and pathologic roles of the Alzheimer’s β-secretase, BACE1. Curr. Alzheimer Res. 2014, 11, 441–449. [Google Scholar] [CrossRef]
- Ricciarelli, R.; Fedele, E. The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind. Curr. Neuropharmacol. 2017, 15, 926–935. [Google Scholar] [CrossRef] [Green Version]
- MacLeod, R.; Hillert, E.-K.; Cameron, R.-T.; Baillie, G.S. The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer’s disease. Future Sci. OA 2015, 1, fso11. [Google Scholar] [CrossRef] [Green Version]
- Vingtdeux, V.; Hamdane, M.; Loyens, A.; Gelé, P.; Drobeck, H.; Bégard, S.; Galas, M.C.; Delacourte, A.; Beauvillain, J.C.; Buée, L.; et al. Alkalizing drugs induce accumulation of amyloid precursor protein by-products in luminal vesicles of multivesicular bodies. J. Biol. Chem. 2007, 282, 18197–18205. [Google Scholar] [CrossRef] [Green Version]
- Vingtdeux, V.; Hamdane, M.; Bégard, S.; Loyens, A.; Delacourte, A.; Beauvillain, J.C.; Buée, L.; Marambaud, P.; Sergeant, N. Intracellular pH regulates amyloid precursor protein intracellular domain accumulation. Neurobiol. Dis. 2021, 25, 686–696. [Google Scholar] [CrossRef]
- Schrader-Fischer, G.; Paganetti, P.A. Effect of alkalizing agents on the processing of the beta-amyloid precursor protein. Brain Res. 1996, 716, 91–100. [Google Scholar] [CrossRef] [PubMed]
- Caporaso, G.L.; Gandy, S.E.; Buxbaum, J.D.; Greengard, P. Chloroquine inhibits intracellular degradation but not secretion of Alzheimer beta/A4 amyloid precursor protein. Proc. Nat. Acad. Sci. USA 1992, 89, 2252–2256. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Melnyk, P.; Vingtdeux, V.; Burlet, S.; Eddarkaoui, S.; Grosjean, M.E.; Larchanché, P.E.; Hochart, G.; Sergheraert, C.; Estrella, C.; Barrier, M.; et al. Chloroquine and chloroquinoline derivatives as models for the design of modulators of amyloid Peptide precursor metabolism. ACS Chem. Neurosci. 2015, 6, 559–569. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gay, M.; Carato, P.; Coevoet, M.; Renault, N.; Larchanché, P.E.; Barczyk, A.; Yous, S.; Buée, L.; Sergeant, N.; Melnyk, P. New phenylaniline derivatives as modulators of amyloid protein precursor metabolism. Bioorg. Med. Chem. 2018, 26, 2151–2164. [Google Scholar] [CrossRef]
- Gay, M.; Evrard, C.; Descamps, F.; Carato, P.; Renault, N.; Coevoet, M.; Eddarkaoui, S.; Baud, C.; Larchanché, P.E.; Buée, L.; et al. A phenotypic approach to the discovery of compounds that promote non-amyloidogenic processing of the amyloid precursor protein: Toward a new profile of indirect β-secretase inhibitors. Eur. J. Med. Chem. 2018, 159, 104–125. [Google Scholar] [CrossRef]
- Moore, S.; Evans, L.D.; Andersson, T.; Portelius, E.; Smith, J.; Dias, T.B.; Saurat, N.; McGlade, A.; Kirwan, P.; Blennow, K.; et al. APP metabolism regulates tau proteostasis in human cerebral cortex neurons. Cell Rep. 2015, 11, 689–696. [Google Scholar] [CrossRef] [Green Version]
- Leroy, K.; Ando, K.; Laporte, V.; Dedecker, R.; Suain, V.; Authelet, M.; Héraud, C.; Pierrot, N.; Yilmaz, Z.; Octave, J.N. Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice. Am. J. Pathol. 2012, 181, 1928–1940. [Google Scholar] [CrossRef]
- Wu, H.Y.; Kuo, P.C.; Wang, Y.T.; Lin, H.T.; Roe, A.D.; Wang, B.Y.; Han, C.L.; Hyman, B.T.; Chen, Y.J.; Tai, H.C. β-Amyloid Induces Pathology-Related Patterns of Tau Hyperphosphorylation at Synaptic Terminals. J. Neuropathol. Exp. Neurol. 2018, 77, 814–826. [Google Scholar] [CrossRef] [Green Version]
- He, Z.; Guo, J.L.; McBride, J.D.; Narasimhan, S.; Kim, H.; Changolkar, L.; Zhang, B.; Gathagan, R.J.; Yue, C.; Dengler, C.; et al. Amyloid-β plaques enhance Alzheimer’s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat. Med. 2018, 24, 29–38. [Google Scholar] [CrossRef]
- Lam, S.; Hérard, A.S.; Boluda, S.; Petit, F.; Eddarkaoui, S.; Cambon, K.; Brainbank Neuro-CEB Neuropathology Network; Picq, J.L.; Buée, L.; Duyckaerts, C.; et al. Pathological changes induced by Alzheimer’s brain inoculation in amyloid-beta plaque-bearing mice. Acta Neuropathol. Commun. 2022, 10, 112. [Google Scholar] [CrossRef] [PubMed]
- Pooler, A.M.; Polydoro, M.; Maury, E.A.; Nicholls, S.B.; Reddy, S.M.; Wegmann, S.; William, C.; Saqran, L.; Cagsal-Getkin, O.; Pitstick, R.; et al. Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer’s disease. Acta Neuropathol. Commun. 2015, 3, 14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pascoal, T.A.; Mathotaarachchi, S.; Shin, M.; Benedet, A.L.; Mohades, S.; Wang, S.; Beaudry, T.; Kang, M.S.; Soucy, J.P.; Labbe, A.; et al. Synergistic interaction between amyloid and tau predicts the progression to dementia. Alzheimer’s Dement. J. Alzheimer Ass. 2017, 13, 644–653. [Google Scholar] [CrossRef]
- Delacourte, A.; Sergeant, N.; Champain, D.; Wattez, A.; Maurage, C.A.; Lebert, F.; Pasquier, F.; David, J.P. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease. Neurology 2002, 59, 398–407. [Google Scholar] [CrossRef] [PubMed]
- Tautou, M.; Eddarkaoui, S.; Descamps, F.; Larchanché, P.E.; El Bakali, J.; Goveas, L.M.; Dumoulin, M.; Lamarre, C.; Blum, D.; Buée, L. A β-Secretase Modulator Decreases Tau Pathology and Preserves Short-Term Memory in a Mouse Model of Neurofibrillary Degeneration. Front. Pharmacol. 2021, 12, 679335. [Google Scholar] [CrossRef]
- Sergeant, N.; Vingtdeux, V.; Eddarkaoui, S.; Gay, M.; Evrard, C.; Le Fur, N.; Laurent, C.; Caillierez, R.; Obriot, H.; Larchanché; et al. PENew piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer’s disease. Neurobiol. Dis. 2019, 129, 217–233. [Google Scholar] [CrossRef]
- Garcia-Alloza, M.; Robbins, E.M.; Zhang-Nunes, S.X.; Purcell, S.M.; Betensky, R.A.; Raju, S.; Prada, C.; Greenberg, S.M.; Bacskai, B.J.; Frosch, M.P. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 2006, 24, 516–524. [Google Scholar] [CrossRef]
- Kamphuis, W.; Mamber, C.; Moeton, M.; Kooijman, L.; Sluijs, J.A.; Jansen, A.H.; Verveer, M.; de Groot, L.R.; Smith, V.D.; Rangarajan, S. GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS ONE 2012, 7, e42823. [Google Scholar] [CrossRef] [Green Version]
- Escartin, C.; Galea, E.; Lakatos, A.; O’Callaghan, J.P.; Petzold, G.C.; Serrano-Pozo, A.; Steinhäuser, C.; Volterra, A.; Carmignoto, G.; Agarwal, A. Reactive astrocyte nomenclature, definitions, and future directions. Nat. Neurosci. 2021, 24, 312–325. [Google Scholar] [CrossRef]
- Liu, S.; Liu, Y.; Hao, W.; Wolf, L.; Kiliaan, A.J.; Penke, B.; Rübe, C.E.; Walter, J.; Heneka, M.T.; Hartmann, T. TLR2 is a primary receptor for Alzheimer’s amyloid β peptide to trigger neuroinflammatory activation. J. Immunol. 2012, 188, 1098–1107. [Google Scholar] [CrossRef] [Green Version]
- Holtman, I.R.; Raj, D.D.; Miller, J.A.; Schaafsma, W.; Yin, Z.; Brouwer, N.; Wes, P.D.; Möller, T.; Orre, M.; Kamphuis, W. Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: A co-expression meta-analysis. Acta Neuropathol. Commun. 2015, 3, 31. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, F.; Grundke-Iqbal, I.; Iqbal, K.; Gong, C.X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci. 2005, 22, 1942–1950. [Google Scholar] [CrossRef]
- Vossel, K.A.; Xu, J.C.; Fomenko, V.; Miyamoto, T.; Suberbielle, E.; Knox, J.A.; Ho, K.; Kim, D.H.; Yu, G.Q.; Mucke, L. Tau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3β. J. Cell Biol. 2015, 209, 419–433. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, S.-L.; Wang, C.; Jiang, T.; Tan, L.; Xing, A.; Yu, J.-T. The Role of Cdk5 in Alzheimer’s Disease. Mol. Neurobiol. 2015, 53, 4328–4342. [Google Scholar] [CrossRef] [PubMed]
- Laurén, J.; Gimbel, D.A.; Nygaard, H.B.; Gilbert, J.W.; Strittmatter, S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009, 457, 1128–1132. [Google Scholar] [CrossRef] [Green Version]
- Vingtdeux, V.; Hamdane, M.; Gompel, M.; Bégard, S.; Drobecq, H.; Ghestem, A.; Grosjean, M.E.; Kostanjevecki, V.; Grognet, P.; Vanmechelen, E.; et al. Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. Neurobiol. Dis. 2005, 20, 625–637. [Google Scholar] [CrossRef]
- Chang, K.A.; Kim, H.S.; Ha, T.Y.; Ha, J.W.; Shin, K.Y.; Jeong, Y.H.; Lee, J.P.; Park, C.H.; Kim, S.; Baik, T.K.; et al. Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration. Mol. Cell. Biol. 2006, 26, 4327–4338. [Google Scholar] [CrossRef] [Green Version]
- Um, J.W.; Nygaard, H.B.; Heiss, J.K.; Kostylev, M.A.; Stagi, M.; Vortmeyer, A.; Wisniewski, T.; Gunther, E.C.; Strittmatter, S.M. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci. 2012, 15, 1227–1235. [Google Scholar] [CrossRef] [Green Version]
- Wahle, T.; Prager, K.; Raffler, N.; Haass, C.; Famulok, M.; Walter, J. GGA proteins regulate retrograde transport of BACE1 from endosomes to the trans-Golgi network. Mol. Cell. Neurosci. 2005, 29, 453–461. [Google Scholar] [CrossRef]
- von Arnim, C.A.; Spoelgen, R.; Peltan, I.D.; Deng, M.; Courchesne, S.; Koker, M.; Matsui, T.; Kowa, H.; Lichtenthaler, S.F.; Irizarry, M.C.; et al. GGA1 acts as a spatial switch altering amyloid precursor protein trafficking and processing. J. Neurosci. 2006, 26, 9913–9922. [Google Scholar] [CrossRef] [Green Version]
- Toh, W.H.; Chia, P.Z.C.; Hossain, M.I.; Gleeson, P.A. GGA1 regulates signal-dependent sorting of BACE1 to recycling endosomes, which moderates Aβ production. Mol. Biol. Cell. 2018, 29, 191–208. [Google Scholar] [CrossRef] [PubMed]
- Nicholls, R.E.; Sontag, J.M.; Zhang, H.; Staniszewski, A.; Yan, S.; Kim, C.Y.; Yim, M.; Woodruff, C.M.; Arning, E.; Wasek, B.; et al. PP2A methylation controls sensitivity and resistance to β-amyloid-induced cognitive and electrophysiological impairments. Pro. Nat. Acad. Sci. USA 2016, 113, 3347–3352. [Google Scholar] [CrossRef] [Green Version]
- Wei, H.; Zhang, H.L.; Wang, X.C.; Xie, J.Z.; An, D.D.; Wan, L.; Wang, J.Z.; Zeng, Y.; Shu, X.J.; Westermarck, J.; et al. Direct Activation of Protein Phosphatase 2A (PP2A) by Tricyclic Sulfonamides Ameliorates Alzheimer’s Disease Pathogenesis in Cell and Animal Models. Neurother. J. Am. Soc. Exp. NeuroTher. 2020, 17, 1087–1103. [Google Scholar] [CrossRef] [PubMed]
- Liu, G.P.; Wei, W.; Zhou, X.; Shi, H.R.; Liu, X.H.; Chai, G.S.; Yao, X.Q.; Zhang, J.Y.; Peng, C.X.; Hu, J.; et al. Silencing PP2A inhibitor by lenti-shRNA interference ameliorates neuropathologies and memory deficits in tg2576 mice. Mol. Ther. 2012, 21, 2247–2257. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Taleski, G.; Schuhmacher, D.; Su, H.; Sontag, J.M.; Sontag, E. Disturbances in PP2A methylation and one-carbon metabolism compromise Fyn distribution, neuritogenesis, and APP regulation. J. Biol. Chem. 2021, 296, 100237. [Google Scholar] [CrossRef]
- Wahle, T.; Thal, D.R.; Sastre, M.; Rentmeister, A.; Bogdanovic, N.; Famulok, M.; Heneka, M.T.; Walter, J. GGA1 is expressed in the human brain and affects the generation of amyloid beta-peptide. J. Neurosci. 2006, 26, 12838–12846. [Google Scholar] [CrossRef] [Green Version]
- Nagele, R.G.; D’Andrea, M.R.; Lee, H.; Venkataraman, V.; Wang, H.Y. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res. 2003, 971, 197–209. [Google Scholar] [CrossRef]
- Lian, H.; Yang, L.; Cole, A.; Sun, L.; Chiang, A.C.; Fowler, S.W.; Shim, D.J.; Rodriguez-Rivera, J.; Taglialatela, G.; Jankowsky, J.L.; et al. NFκB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer’s disease. Neuron 2015, 85, 101–115. [Google Scholar] [CrossRef] [Green Version]
- Shi, Q.; Chowdhury, S.; Ma, R.; Le, K.X.; Hong, S.; Caldarone, B.J.; Stevens, B.; Lemere, C.A. Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Sci. Trans. Med. 2017, 9, eaaf6295. [Google Scholar] [CrossRef] [Green Version]
- Wu, T.; Dejanovic, B.; Gandham, V.D.; Gogineni, A.; Edmonds, R.; Schauer, S.; Srinivasan, K.; Huntley, M.A.; Wang, Y.; Wang, T.M.; et al. Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy. Cell Rep. 2019, 28, 2111–2123.e6. [Google Scholar] [CrossRef] [Green Version]
- Hong, S.; Beja-Glasser, V.F.; Nfonoyim, B.M.; Frouin, A.; Li, S.; Ramakrishnan, S.; Merry, K.M.; Shi, Q.; Rosenthal, A.; Barres, B.A.; et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 2016, 352, 712–716. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Song, J.; Kim, O.Y. Perspectives in Lipocalin-2: Emerging Biomarker for Medical Diagnosis and Prognosis for Alzheimer’s Disease. Clin. Nutr. Res. 2018, 7, 1–10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Naudé, P.J.; Nyakas, C.; Eiden, L.E.; Ait-Ali, D.; van der Heide, R.; Engelborghs, S.; Luiten, P.G.; De Deyn, P.P.; den Boer, J.A.; Eisel, U.L. Lipocalin 2: A novel component of proinflammatory signaling in Alzheimer’s disease. FASEB J. 2012, 26, 2811–2823. [Google Scholar] [CrossRef] [Green Version]
- McDonald, C.L.; Hennessy, E.; Rubio-Araiz, A.; Keogh, B.; McCormack, W.; McGuirk, P.; Reilly, M.; Lynch, M.A. Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer’s disease. Brain Behav. Immun. 2016, 58, 191–200. [Google Scholar] [CrossRef]
- Jana, M.; Palencia, C.A.; Pahan, K. Fibrillar amyloid-beta peptides activate microglia via TLR2: Implications for Alzheimer’s disease. J. Immun. 2008, 181, 7254–7262. [Google Scholar] [CrossRef] [Green Version]
- Fiebich, B.L.; Batista, C.R.A.; Saliba, S.W.; Yousif, N.M.; de Oliveira, A.C.P. Role of Microglia TLRs in Neurodegeneration. Front. Cell. Neurosci. 2018, 12, 329. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lax, N.; Fainstein, N.; Nishri, Y.; Ben-Zvi, A.; Ben-Hur, T. Systemic microbial TLR2 agonists induce neurodegeneration in Alzheimer’s disease mice. J. Neuroinlfam. 2020, 17, 55. [Google Scholar] [CrossRef]
- Fitz, N.F.; Wolfe, C.M.; Playso, B.E.; Biedrzycki, R.J.; Lu, Y.; Nam, K.N.; Lefterov, I.; Koldamova, R. Trem2 deficiency differentially affects phenotype and transcriptome of human APOE3 and APOE4 mice. Mol. Neurodegener. 2020, 15, 41. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Zhang, X.; Song, Q.; Hou, Y.; Liu, J.; Sun, Y.; Wang, P. Characterization of the chromatin accessibility in an Alzheimer’s disease (AD) mouse model. Alzheimer Res. Therap. 2020, 12, 29. [Google Scholar] [CrossRef]
- Wang, S.; Sudan, R.; Peng, V.; Zhou, Y.; Du, S.; Yuede, C.M.; Lei, T.; Hou, J.; Cai, Z.; Cella, M.; et al. TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways. Cell 2022, 185, 4153–4169.e19. [Google Scholar] [CrossRef]
- Chatterjee, P.; Pedrini, S.; Stoops, E.; Goozee, K.; Villemagne, V.L.; Asih, P.R.; Verberk, I.M.W.; Dave, P.; Taddei, K.; Sohrabi, H.R.; et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease. Trans. Psychiatry 2021, 11, 27. [Google Scholar] [CrossRef] [PubMed]
- Schöll, M.; Carter, S.F.; Westman, E.; Rodriguez-Vieitez, E.; Almkvist, O.; Thordardottir, S.; Wall, A.; Graff, C.; Långström, B.; Nordberg, A. Early astrocytosis in autosomal dominant Alzheimer’s disease measured in vivo by multi-tracer positron emission tomography. Sci. Rep. 2015, 5, 16404. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Verberk, I.M.W.; Thijssen, E.; Koelewijn, J.; Mauroo, K.; Vanbrabant, J.; de Wilde, A.; Zwan, M.D.; Verfaillie, S.C.J.; Ossenkoppele, R.; Barkhof, F.; et al. Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimer Res. Ther. 2020, 12, 118. [Google Scholar] [CrossRef] [PubMed]
- Liddelow, S.A.; Guttenplan, K.A.; Clarke, L.E.; Bennett, F.C.; Bohlen, C.J.; Schirmer, L.; Bennett, M.L.; Münch, A.E.; Chung, W.S.; Peterson, T.C.; et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 2017, 541, 481–487. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Callizot, N.; Estrella, C.; Burlet, S.; Henriques, A.; Brantis, C.; Barrier, M.; Campanari, M.L.; Verwaerde, P. AZP2006, a new promising treatment for Alzheimer’s and related diseases. Sci. Rep. 2021, 11, 16806. [Google Scholar] [CrossRef]
- Barnes, C.A. Memory deficits associated with senescence: A neurophysiological and behavioral study in the rat. J. Comp. Physiol. Psychol. 1979, 93, 74–104. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tautou, M.; Descamps, F.; Larchanché, P.-E.; Buée, L.; El Bakali, J.; Melnyk, P.; Sergeant, N. A Polyaminobiaryl-Based β-secretase Modulator Alleviates Cognitive Impairments, Amyloid Load, Astrogliosis, and Neuroinflammation in APPSwe/PSEN1ΔE9 Mice Model of Amyloid Pathology. Int. J. Mol. Sci. 2023, 24, 5285. https://doi.org/10.3390/ijms24065285
Tautou M, Descamps F, Larchanché P-E, Buée L, El Bakali J, Melnyk P, Sergeant N. A Polyaminobiaryl-Based β-secretase Modulator Alleviates Cognitive Impairments, Amyloid Load, Astrogliosis, and Neuroinflammation in APPSwe/PSEN1ΔE9 Mice Model of Amyloid Pathology. International Journal of Molecular Sciences. 2023; 24(6):5285. https://doi.org/10.3390/ijms24065285
Chicago/Turabian StyleTautou, Marie, Florian Descamps, Paul-Emmanuel Larchanché, Luc Buée, Jamal El Bakali, Patricia Melnyk, and Nicolas Sergeant. 2023. "A Polyaminobiaryl-Based β-secretase Modulator Alleviates Cognitive Impairments, Amyloid Load, Astrogliosis, and Neuroinflammation in APPSwe/PSEN1ΔE9 Mice Model of Amyloid Pathology" International Journal of Molecular Sciences 24, no. 6: 5285. https://doi.org/10.3390/ijms24065285